Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the other hand, next quarter’s revenue guidance of $1 billion was less impressive, ...

While the company no longer manufactures the radiographic markers, healthcare providers are still advised to monitor patients who have had them implanted.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110 th Scientific Assembly and Annual Meeting of the ...

July 9 (Reuters) - Private equity groups Blackstone and TPG are seeking more than $4 billion for medical technology firm Hologic's surgical unit, the Financial Times reported on Thursday, citing ...

Medical technology company Hologic (NASDAQ:HOLX) announced in Q3 CY2025, with sales up 6.2% year on year to $1.05 billion. Its non-GAAP profit of $1.13 per share was 2.7% above analysts’ consensus ...

Hologic is asking women to #BustTheMyth this Breast Cancer Awareness Month. The provider of breast health products has put a set of myths about cancer, such as the belief women without a family ...

On Friday, the FDA warned against using Hologic Inc.’s (NASDAQ:HOLX) BioZorb Marker products and urged healthcare facilities to return all unused lots. This follows Hologic’s voluntary recall of the ...

Hologic HOLX is set to release third-quarter fiscal 2025 results on July 30, after the closing bell. The Zacks Consensus Estimate for third-quarter earnings per share (EPS) suggests a 0.9% decrease ...

Hologic’s recall of its BioZorb Markers due to complications with the implanted device were recently identified as Class I by FDA after 71 injuries were reported as being related to BioZorb Markers.